Therefore, the purpose of our analysis was to explore the cost-effectiveness of palbociclib plus fulvestrant in the second-line treatment of women with HR+/HER2- advanced breast cancer based on a dynamic Markov model from the perspective of the Chinese healthcare system. This evidence concerns the gene ERBB2 and breast carcinoma.